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Occurrence of hypoglycemia in diabetes patients is very rare. We report here a case of frequent hypoglycemic attacks
caused by inappropriate endogenous hyperinsulinemia in a female patient with poorly controlled diabetes and protein-losing
gastroenteropathy. The blood glucose proﬁles of the patient were unstable. Results of the fasting test performed to investigate
the cause of hypoglycemia suggested endogenous hyperinsulinism. Repeated selective arterial calcium injection tests suggested
that hyperinsulinemia might be extrapancreatic in origin. However, eﬀorts to detect a responsible lesion such as insulinoma
were unsuccessful. Octreotide was used for the treatment of hypoglycemia and protein-losing gastroenteropathy. After treatment,
although her leg edema caused by hypoalbuminemia persisted, hypoglycemia almost disappeared.
1.Introduction
Hypoglycemia is a clinical syndrome with diverse causes
characterized by low levels of plasma glucose [1]. When it
occurs in a patient with known diabetes, the blood glucose
proﬁles are unstable or sometimes ameliorated [2]. To
evaluate such hypoglycemia, one should consider many eti-
ologies such as increased insulin sensitivity, increased insulin
bioavailability, inadequate carbohydrate intake, mismatch of
insulin and food intake, decreased clearance of insulin/oral
agent, hypothyroidism, impaired counterregulation, and
eﬀect of some drugs [3]. Further, related serum tests such as
those for fasting blood glucose, immunoreactive insulin, and
insulin autoantibody were performed.
Endogenous hyperinsulinemic hypoglycemia such as
insulinoma or nesidioblastosis is one of important causes
of hypoglycemia and is suggested by a positive fasting test.
To diagnose insulinoma, computed tomography (CT) scan,
magnetic resonance imaging (MRI) scan, and endoscopic
ultrasound were performed to localize the possible lesion.
However, the diagnostic values of these tests are not high if
the underlying insulinoma is a very tiny tumor or may be of
extrapancreatic origin. Alternatively, if nesidioblastosis is the
cause of hypoglycemia, the lesion is diﬃcult to be depicted
because it is characterized by diﬀuse or disseminated pro-
liferation of islet cells arising from pancreatic ducts or
ductules and is generally diagnosed only by pathology [4, 5].
To diagnose endogenous hyperinsulinemia functionally and
anatomically,aselectivearterialcalciuminjection(SACI)test
is very useful [6].
Here, we report an extremely rare case of endogenous
hyperinsulinemic hypoglycemia without distinct mass in2 Case Reports in Medicine
a patient with poorly controlled diabetes and protein-losing
gastroenteropathy. Moreover, we discuss the unusual clinical
presentation, especially relating to the results obtained with
SACI tests, the pathophysiology, and eﬀective management
of such cases.
2. Case Presentation
A 52-year-old female with a history of admission to the
hospital 5 times in the last 5 years because of frequent
hypoglycemic attacks was admitted to our hospital.
At the age of 36, her urine examination showed excessive
glucose levels but she did not receive further medical
treatment. The following year, she consulted a doctor due
to general malaise and bilateral lower leg edema. She was
thendiagnosedwithdiabetesmellitusandhypoalbuminemia
of unknown cause. Glibenclamide was administered for
the treatment of diabetes at age of 40, but poor control
persisted. She was referred to our hospital for the ﬁrst
time at the age of 43 because of exacerbation of her lower
leg edema. Protein-losing gastroenteropathy (PLGE) due to
idiopathic gastrointestinal lymphangiectasia was diagnosed
by functional and histopathological examinations. She had
been treated with elemental diet and steroid therapy for
her PLGE, but those treatments were not eﬀective. At
the same time, insulin therapy was started because of the
poorly controlled diabetes (HbA1c, approximately 10%).
After the age of 47, her average blood glucose levels were
keeping consistently high (300 to 400mg/dL) and even
hypoglycemic attacks had been recognized. When she was
hospitalized at the age of 48, the cause of the hypoglycemic
attacks was unidentiﬁed (2004). Around the age of 50,
the frequency of hypoglycemic attacks (deﬁned as blood
glucose level less than 70mg/dL) had increased to about
40 times per month. The attacks occurred at postprandial
and preprandial times. Her medication history suggested
that hypoglycemia was not related to her insulin therapy.
Precise examination of hypoglycemia was performed during
the current hospitalization at the age of 52.
On admission, her body height was 137cm and body
weight was 44kg (BMI, 23.4kg/m2). Blood pressure was
128/78mmHg and heart rate was 87. Physical examination
revealed bilateral lower leg pitting edema, no Achilles tendon
reﬂexes, and reduced sensation of vibration (C128Hz, 4s
(rt.)/4s (lt.)). Chest X-ray revealed no pleural eﬀusions and
no cardiomegaly. Diabetic complications were conﬁrmed,
that is, bilateral proliferative retinopathy, nephropathy (stage
2), and peripheral neuropathy. She was treated with a com-
bination of rapid-acting and NPH insulin injection for her
diabetes. The results of laboratory tests were as follows: total
protein: 4.0g/dL; serum albumin: 2.3g/dL; total cholesterol:
172mg/dL; triglyceride: 104mg/dL; HDL-c: 47.4mg/dL;
LDL-c: 116.7mg/dL; creatinine: 0.49mg/dL; HbA1c: 15.5%;
urinary C-peptide: 125μg/day; anti-GAD and anti-IA-2
antibodies: negative; urinary microalbumin: 73.8mg/g·Cre;
creatinine clearance: 109.4mL/min/m2. Blood glucose pro-
ﬁles appeared unstable, with periodic (2 to 3 days) alter-
nation between hyperglycemia (>300mg/dL) and hypo-
glycemia (<70mg/dL). Representative blood glucose proﬁles
are shown in Figure 1(a), and the frequency of hypoglycemia
is shown in Figure 1(b). A glucagon loading/stimulation test
revealed that the ability of insulin secretion was retained
(ΔCPR = 4.8ng/mL). No abnormalities were found in other
endocrine hormones.
Because the hypoglycemic attacks occurred at a time
after cessation of insulin injections suﬃciently longer than
the eﬀective time of the insulin, we were convinced that
hypoglycemia was not related to the injections. Therefore,
we suspected that it was induced by an endogenous cause.
The result of a fasting test was positive (Figure 2). After a
17h fast, hypoglycemia (plasma glucose 45mg/dL) appeared
and serum insulin concentration was 9.92μU/mL (normal,
<6.0), C-peptide level was 0.98ng/mL (<0.6), and proinsulin
level was 15.3pmol/L (<5.0). Service’s and Turner’s criteria
for diagnosing insulinoma were satisﬁed (Grunt 4.54 (posi-
tive,<2.5),Fajans0.22(>0.3),Turner66.1(>50),andService
9.92 (>6)). Serum C-peptide and proinsulin levels at the
time of hypoglycemia attack were signiﬁcantly high, and the
values satisﬁed the criteria for hyperinsulinism deﬁned by
Service [1]. Also, the proinsulin level was above 5pmol/L,
and this parameter and threshold level have been reported as
thebestcriteriafordiagnosisofendogenoushyperinsulinism
during the fasting test [7]. Counterregulatory response to
hypoglycemia was not impaired; before and at the time of
hypoglycemia, testing showed the following respective levels:
glucagon 150pg/mL and 230pg/mL; cortisol 6.09μg/dL and
27.45μg/dL; growth hormone 0.33ng/mL and 11.70ng/mL;
adrenaline <10pg/mL and 583pg/mL. Tests for both anti-
insulin antibody and anti-insulin receptor antibody were
negative. We excluded the speciﬁc hypoglycemic conditions
induced by medicines, insulin autoimmunity, factitious
hypoglycemia, and other conditions/diseases such as renal
failure or liver cirrhosis. We did not measure plasma
sulfonylurea concentration as we were aware that the patient
had not been taking the medicine. To investigate the
possible involvement of glucose-dependent insulinotropic
polypeptide (GIP) or glucagon-like peptide 1 (GLP-1)
in the hypoglycemia, we measured serum concentrations
of total GIP (Human GIP Assay Kit, Immuno-Biological
Laboratories,Fujioka,Japan)andtotalGLP-1(YK160GLP-1
EIA Kit, Yanaihara Institute, Fujinomiya, Japan) by enzyme-
linked immunosorbent assays in her fasting, postprandial,
and hypoglycemic state. Serum concentrations of total GIP
were 7.6, 30.2, and 6.0pg/mL, whereas those of total GLP-
1 were 4.7, 4.2, and 4.1ng/mL in fasting, postprandial, and
hypoglycemic state, respectively. Taken together, these results
suggested that inappropriate endogenous hyperinsulinemia
was responsible for her hypoglycemia, possibly due to
insulinoma, nesidioblastosis, or β cell dysfunction.
Thus far, all eﬀorts for obtaining diagnostic imaging
of an insulinoma via CT scan, MRI scan, and endoscopic
ultrasound were unsuccessful. SACI tests with calcium
gluconate (Ca2+ 0.025mEq/kg) were performed twice in
2004 (age 48) and 2008 (age 52). In keeping with other
researchers, an increment in plasma immunoreactive insulin
levels greater than 2-fold over prestimulation levels was
considered indicative of a tumor or other responsive lesion
in the vascular territory of the artery studied [8]. TheCase Reports in Medicine 3
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Figure 1: Representative blood glucose proﬁles before treatment. Blood glucose proﬁle and the dose of each insulin injection are shown (a).
The duration between ticks on the X-axis represents 24h. The frequency of hypoglycemia, deﬁned as below 70mg/dL of blood glucose, is
shown (b).
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Figure 2: The result of the fasting test. Blood glucose levels were
monitored. After 17h of fasting, the blood glucose level decreased
to 45mg/dL.
results, conﬁrmed twice, were positive only after stim-
ulations of the supramesenteric artery (SMA) (2.53-fold
increase in 2004 and 3.36 in 2008 versus before stimulation;
Figures 3(a) and 3(b), resp.). No anatomical variant was
apparent on review of the angiogram, but there seemed to
be backﬂow slightly in the gastroduodenal artery (GDA) on
the examination only in 2008. Exploratory laparotomy was
refused by the patient and her family.
Since she had been suﬀering mostly from frequent hypo-
glycemic attacks, we focused primarily on the management
of hypoglycemia by medication. We considered the use
of octreotide (Sandostatin, Novartis, Basel, Switzerland),
a long-acting somatostatin analog, because this medicine
suppresses insulin secretion [9] and has been reported to
be eﬀective for PLGE due to idiopathic gastrointestinal
lymphangiectasia [10]. At ﬁrst, we tried a single dose (50μg)
of octreotide to evaluate its eﬀects on serum insulin and
glucose levels (Figure 4). As we observed no remarkable
changes in glucose levels and suppression of insulin levels,
we started her on octreotide (50μg, twice a day) for 2 weeks,
monitoring itstolerability.Sincealmostnosideeﬀectsexcept
for controllable constipation were determined, we switched
to octreotide LAR (Sandostatin LAR, Novartis, 20mg per
month), which is a very long-acting octreotide. After using
octreotide LAR for 4 months, although hyperglycemia
was uncontrollable even with multiple insulin injections
(Figure 5(a)), the frequency of hypoglycemic attacks was
surprisingly reduced (Figure 5(b)). This eﬀect was sustained
for 20 months until her death from acute heart failure (54
years, 2010). On the other hand, serum albumin was slightly
increased (2.3g/dL and 3.0g/dL; before and after treatment,
resp.), but her leg edema was unchanged.
3. Discussion
To the best of our knowledge, this is the ﬁrst report of
an extremely rare case with the following four character-
istics: (1) frequent hypoglycemia induced by endogenous
hyperinsulinemia derived from an unusual origin without
distinct mass, (2) hypoglycemia in a patient with known4 Case Reports in Medicine
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Figure 3: Results of SACI tests at 2004 (a) and 2008 (b). A vascular catheter was located to each speciﬁc artery ( splenic (distal),  splenic
(proximal),  gastroduodenal,  supramesenteric, • proper hepatic, ◦ inferior pancreaticoduodenal artery). Blood samples were collected
from the hepatic vein for measuring insulin concentrations before and after stimulation by calcium gluconate (Ca2+ 0.025mEq/Kg).
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Figure 4: The eﬀects of a single dose of octreotide (50μg) on blood
glucose and serum immunoreactive insulin levels.
diabetes, (3) coexistence with PLGE, and (4) amelioration of
hypoglycemia by treatment with octreotide.
The most interesting and important point in this case
is that positive results from both SACI tests were obtained
only via SMA stimulation. The SACI test is an important
and useful method for localization of the lesion responsible
for hyperinsulinism such as insulinoma. A 2-fold or greater
stepup in hepatic vein insulin concentration from baseline
afterarterialcalciuminjectionconstitutesapositiveresponse
[8]. Using this criteria, Guettier et al. reported that a positive
response was observed in a single vessel in 16 of 45 cases
(36%) and in two or more vessels in 25 of 45 cases (53%)
[11]. The reasons for this are unclear and may relate to
overlap in arterial territory, tumor behavior, or problems
related to the speciﬁcity of the test. When multiple arterial
injections elicit a positive response, the dominant response
is taken as the site of tumor localization. The sensitivity of
SACI in localizing insulinomas has ranged from 88% to 94%
[8, 12, 13], and a false positive rate is reported to be 4% [11].
We performed SACI twice in our case when she was 48 and
52 years old, and positive results were obtained reproducibly
in both tests for stimulations performed only via SMA. We
believe this was reliable evidence for SMA localization. In
terms of vascular territories for the pancreas, SMA supplies
the uncinate process and secondarily the pancreatic head in
addition to the mesentery, and GDA supplies the pancreatic
head and secondarily the uncinate process. If a lesion existed
within the pancreas in this patient, the positive results via
SMA stimulation suggest that the lesion would have been
located in the head/uncus of the pancreas. If a lesion was
located in that part of the pancreas, a positive result couldCase Reports in Medicine 5
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Figure 5: Representative blood glucose proﬁles after the treatment of octreotide LAR for 4 months. Blood glucose proﬁle and the dose of
each insulin injection are shown (a). The duration between ticks on the X-axis represents 24h. The frequency of hypoglycemia, deﬁned as
below 70mg/dL of blood glucose, is shown (b).
alsohavebeenobtainedfromGDAstimulation.However,we
failed to conﬁrm positive GDA stimulation twice. Because a
backﬂow into GDA was observed by angiography at the age
of 52, the stimulation via GDA might have been insuﬃcient.
Therefore, an additional and selective injection into the
inferior pancreaticoduodenal artery (IPDA), the branching
artery of SMA leading to the pancreatic head, was performed
to investigate a possible lesion in the head/uncus of the
pancreas[14,15].Consequently,stimulationviaIPDAinthis
case was negative on the second SACI test. Taken together,
weconcludedthathypoglycemiawasinducedbyendogenous
hyperinsulinism and the responsible lesion possibly existed
in the vascular territory of SMA that was of extrapancreatic
origin (including the surroundings of the pancreas).
The delayed maximum reaction time (120s) observed in
both SACI tests was characteristic. In general, the maximum
reaction time in the SACI test is observed 30–60s after
calciuminjection. It hasbeen reported thatmalignant insuli-
nomas showed a slow increase with a peak observed 90–120s
after stimulation, depending on size and neovascularization
[16]. However, there were no signs or suggestions from
imaging of a malignancy in our case. A few cases of benign
insulinoma showing a delayed response in the SACI test have
been reported [17, 18]. Tsagarakis et al. reported a case of
insulinoma located in the junction between the neck and
bodyofthepancreas,andtheSACItestofthepatientshowed
a maximum rise at 180s after stimulation from GDA [17].
O’Shea et al. reported a similar case of insulinoma in the
pancreatic tail, and the SACI test showed the maximum
rise at 120s after stimulation from the splenic artery [18].
The reason why the maximum reaction was delayed in these
cases has not been clariﬁed; however, it may have been due
to slow and/or complicated blood ﬂow or altered β cell
tumor responses. Taking the results of these reports into
account, the delayed response observed in our case should
be considered as signiﬁcant.
The diﬀerential diagnosis of endogenous hyperinsu-
linemic hypoglycemia in this patient listed extrapancre-
atic insulinoma and nesidioblastosis. Filipi and Higgins
reported that the frequency of ectopic insulinoma was 1.96%
(20/1018) including the wall of the duodenum (5/20), near
the tail of the pancreas (3/20), near the pancreas (5/20),
gastrosplenic omentum (2/20), the paraduodenal region
(2/20), and between the head of the pancreas and liver (1/20)
[19]. Another report showed that the frequency of ectopic
islet tumor was 2.26% (9/398) [20]. According to the SACI
results in this case including positive SMA and negative GDA
and IPDA stimulations, an undetectable ectopic insulinoma
may have been present in the vascular territory of SMA.
Nesidioblastosis has traditionally been thought to be the
most common cause of endogenous hyperinsulinism in
neonates and infants [4]. By comparing clinical features
with insulinoma, hypoglycemia arising from nesidioblastosis
tends to occur at postmeal times, as partly seen in our
case. Considering these points, it may be possible that a
nesidioblastic change occurred in the ectopic pancreas of the
patient. Alternatively, nesidioblastosis might have existed in
the head of the pancreas and not been detected if the GDA
and IPDA stimulations to the patient were insuﬃcient.
The development of endogenous hyperinsulinemic hy-
poglycemia in patients with known diabetes is extremely
rare. Most of these cases have been due to benign insulino-
mas. In addition, islet hyperplasia and nesidioblastosis were
reported in hypoglycemic patients with diabetes [21]. The
blood glucose proﬁles for diabetes accompanied by insuli-
noma are unstable, similar to those in our case as shown6 Case Reports in Medicine
inFigure 1(a).Thesimilarityoftheproﬁlesconvincedusthat
our patient also had either insulinoma or nesidioblastosis.
It is diﬃcult to know the pathogenic relationship between
her existing diabetes and hyperinsulinemia. Chronic insulin
exposure alters insulin signaling in vitro. For example, pro-
tein levels of insulin receptor substrate-1, which play impor-
tantrolesininsulinsignaling, arereducedinadipocytes [22].
Insulin resistance is shown in insulinoma patients as com-
pared with healthy nonobese controls by hyperinsulinemic
clamp studies, in addition to obese type 2 diabetic patients
[23]. For our case, these results suggested that altered insulin
sensitivity induced by hyperinsulinemia may have partially
contributed to her unstable blood glucose control.
The relationship between hyperinsulinemia and gut
diseases including PLGE and intestinal lymphangiectasia
remains unclear. Gut secretes incretins such as GIP and
GLP-1, and both peptides stimulate insulin secretion from
pancreatic β cells [24]. In Caucasian subjects, serum concen-
trations of these peptides are increased in response to meal
ingestion compared with fasting state [25, 26]. Additionally,
increased GLP-1 concentration has been implicated in
reactivehypoglycemiainpatientswithgastrectomyorgastric
bypass surgery [27, 28]. Given the insulinotropic properties
of incretins, we hypothesized that GIP or GLP-1 might be
involved in her hypoglycemia. As shown in Section 2,w e
observed a rise in GIP but not in GLP-1 concentration in
postprandial state. Interestingly, a recent study in Japanese
subjectshasdemonstratedthatnoobviouspeakoftotalGLP-
1 was seen after meal ingestion [29]. The racial diﬀerence in
incretin system may account for the loss of GLP-1 response
after meal ingestion. No signiﬁcant changes were seen in
the concentrations of both peptides in hypoglycemic state
compared with those in fasting state. Although our measure-
mentswerelimitedinnumber,theseresultssuggestlittlepos-
sibility of the involvement of incretins in her hypoglycemia.
We considered a medication for appropriately raising
her blood glucose levels and thus alleviating the symptom
of hypoglycemia. The possible medicines listed were glu-
cocorticoid, glucagon, diazoxide, somatostatin analog, and
streptozotocin. Previously, we administered prednisolone
for the treatment of PLGE but the treatment was not
eﬀective. Treatment of glucagon is diﬃcult to continue for a
patient because it needs to be administered intramuscularly
or intravenously. Streptozotocin is an approved medicine
for treatment of malignant islet cell tumor by destructing
islet cells. Because the eﬀect of the drug is irreversible
to islet cells, thereby exacerbating diabetes inevitably, we
could not select this medicine. Diazoxide was originally
developed as an antihypertensive medicine but later found to
inhibit insulin secretion by activating the potassium channel
in β cells. However, approximately half of the patients
administered diazoxide suﬀered from several adverse eﬀects
including edema [30]. We worried about exacerbation of her
existing edema caused by PLGE with diazoxide treatment. In
addition, it was not available commercially in Japan at the
time of treatment for this patient. Novel diazoxide analogs
that have potent and selective activation of the pancreatic β
celltypeKATP channelhavebeendevelopedrecently[31],and
these medicines will be used for an alternative treatment in
future.
Octreotide, a somatostatin analog, is eﬀective against
endogenous hyperinsulinemic hypoglycemia by inhibiting
insulin secretion [9]. Furthermore, this medicine has also
been used for the treatment of PLGE [10]. Because of these
properties, we gave preference to the use of octreotide.
Vezzosi et al. recently reported that octreotide was eﬀective
against hyperinsulinemic hypoglycemia in 14 of 21 patients
[9]. Octreotide was also eﬀective in raising blood glucose
in hypoglycemia caused by sulfonylurea [32]. On the other
hand, octreotide improved blood glucose control in com-
bination with insulin in diabetes by inhibiting glucagon
secretion and intestinal absorption [33]. The addition of
octreotide to insulin therapy in diabetic patients has been
reportedtogiveimprovedglycemiccontroldespitereduction
of insulin dose [34]. Therefore, since octreotide suppresses
bothinsulinandglucagonsecretion,itcouldnotbepredicted
whether blood glucose levels would increase or decrease
with this medicine for this patient. Therefore, we ﬁrst
conﬁrmed its tolerability in the patient by a single-dose
test and subsequent 2-week administration. After treatment
with octreotide, the frequency of hypoglycemic attacks was
dramatically reduced and her quality of life was greatly
improved, although her blood glucose remained high.
Octreotide increased her serum albumin slightly, but her leg
edema was unchanged.
Regarding the side eﬀects of long-term use of octreotide,
Vezzosi et al. reported that only one patient had a symp-
tomatic biliary lithiasis that appeared to be caused by the
medicine among 11 patients who received treatment with
the medicine over 6 months [9]. During the 20-month
treatment in our case, we recognized no apparent side
eﬀects. Treatment with the somatostatin analog has been
shown to shrink the size of some endocrine tumors [35, 36].
However, there have been no reports on such an eﬀect of the
drug on insulinoma to date. When using octreotide, careful
monitoring is needed, and one needs to weigh the beneﬁts
against the side eﬀects.
To our knowledge, this is the ﬁrst report of a diabetic
patient with PLGE diagnosed with endogenous hyperinsu-
linemic hypoglycemia without distinct mass. We managed
frequent hypoglycemic attacks with octreotide eﬀectively.
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